[Preclinical investigation of Mn(II)-diethylenetriaminepentaacetate (Mangapentetate) as paramagnetic contrast agent for magnetic resonance tomography].
The preclinical evaluation of 0.5 M solution of a manganese(II)-DTPA complex (Mangapentetate, Pentamang) has been carried out in order to test the ability of manganese to be used as substitute for potentially toxic gadolinium in paramagnetic contrast agents in the MRI clinical routines. The toxicologic tests of the Mn(II) - DTPA were carried out in mice, rats, and rabbits. Liquid phantoms served for direct comparison of the ability of Mn(II) - DTPA to increase the intensity of T1-weighted SE-images to the contrast properties of the Gd(III) - DTPA (Magnevist). Normal healthy rabbits (n = 12) were used for quantification of the imaging ability of Mn(II) - DTPA. The value of LD50 in rabbits was above 10 ml/kg, rather close to that one of Gd(III) - DTPA. An increase in intensity of the T1-weighted images induced by addition of Mn(II) - DTPA in phantom tests did not differ significantly from the values obtained with Gadopentetate. Mn(II) - DTPA delivered prominent enhancement of normal kidneys in healthy rabbits as well as chest tumors in dogs.